Table 1 Baseline characteristics of the study population, overall and according to cIMT status at baseline. pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood pressure; eGFR, estimated glomerular filtration rate
Variable | Total study population | cIMT < 0.9 mm | cIMT ≥ 0.9 mm | P Value |
|---|---|---|---|---|
n = 672 | 474 | 198 | ||
Age, mean ± SD, y | 51.5 ± 4.7 | 50.9 ± 4.7 | 52.9 ± 4.4 | < 0.001 |
Men, n (%) | 215 (32.0) | 127 (26.8) | 88 (44.4) | < 0.001 |
Body mass index, mean ± SD, kg/m2 | 25.2 ± 3.2 | 24.8 ± 3.2 | 26.0 ± 3.1 | < 0.001 |
pSBP, mean ± SD, mmHg | 122.5 ± 10.0 | 121.7 ± 10.1 | 124.5 ± 9.4 | 0.001 |
pDBP, mean ± SD, mmHg | 72.4 ± 7.5 | 72.2 ± 7.4 | 72.9 ± 7.7 | 0.179 |
eGFR, mean ± SD, mL/min per 1.73 m2 | 99.6 ± 9.8 | 100.7 ± 9.3 | 96.9 ± 10.5 | < 0.001 |
Current smoking, n (%) | 141 (21.0) | 82 (17.3) | 59 (29.8) | < 0.001 |
Current drinking, n (%) | 182 (27.1) | 117 (24.7) | 65 (32.8) | 0.030 |
Dyslipidaemia, n (%) | 451 (67.1) | 308 (65.0) | 143 (72.2) | 0.068 |
Diabetes mellitus, n (%) | 89 (13.2) | 50 (10.5) | 39 (19.7) | 0.001 |
Cardiovascular disease, n (%) | 24 (3.6) | 10 (2.1) | 14 (7.1) | 0.003 |
Lipid-lowering medication, n (%) | 34 (5.1) | 21 (4.5) | 13 (6.6) | 0.251 |
Hypoglycaemic medication, n (%) | 35 (5.2) | 19 (4.0) | 16 (8.1) | 0.029 |